Gyre Therapeutics (GYRE) Current Assets (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Current Assets of $91.7 million for Q1 2026, up 34.02% year-over-year from $68.4 million in Q1 2025, and down 10.39% quarter-over-quarter from $102.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Current Assets (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Current Assets for 17 consecutive years, with $91.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 34.02% year-over-year to $91.7 million; the TTM figure through Mar 2026 stood at $91.7 million (up 34.02% YoY), while the FY2025 annual figure was $102.4 million, up 58.01% from the prior year.
- Current Assets retreated to $91.7 million in Q1 2026 per GYRE's latest filing, from $102.4 million in the prior quarter.
- Across five years, Current Assets topped out at $102.4 million in Q4 2025 and bottomed at $5.1 million in Q3 2023.
- Historically, Current Assets has averaged $57.1 million across 5 years, with a median of $57.2 million in 2023.
- Annual changes were most pronounced in 2023 — Current Assets sank 90.63% — and 2024, when it soared 967.99%.
- Gyre Therapeutics' Current Assets stood at $49.7 million in 2022, then climbed by 15.24% to $57.2 million in 2023, then climbed by 13.22% to $64.8 million in 2024, then soared by 58.01% to $102.4 million in 2025, then dropped by 10.39% to $91.7 million in 2026.
- Business Quant data shows GYRE's Current Assets at $91.7 million in Q1 2026, $102.4 million in Q4 2025, and $98.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 122.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.07 Mn |
| Mar 31, 2026 | 91.73 Mn |
| Dec 31, 2025 | 102.37 Mn |
| Sep 30, 2025 | 98.58 Mn |
| Jun 30, 2025 | 91.29 Mn |
| Mar 31, 2025 | 68.45 Mn |
| Dec 31, 2024 | 64.79 Mn |
| Sep 30, 2024 | 54.81 Mn |
| Jun 30, 2024 | 53.52 Mn |
| Mar 31, 2024 | 62.72 Mn |
| Dec 31, 2023 | 57.22 Mn |
| Sep 30, 2023 | 5.13 Mn |
| Jun 30, 2023 | 7.62 Mn |
| Mar 31, 2023 | 14.01 Mn |
| Dec 31, 2022 | 49.65 Mn |
| Sep 30, 2022 | 30.25 Mn |
| Jun 30, 2022 | 81.31 Mn |
| Mar 31, 2022 | 36.70 Mn |
| Dec 31, 2021 | 51.48 Mn |
| Sep 30, 2021 | 73.96 Mn |